Table 4 Overview of the literature focusing on external radiotherapy for anal canal carcinoma
From: Interstitial high-dose rate brachytherapy as boost for anal canal cancer
Authors (Year) | EBT type | # pts | Median FU (months) | Median EBRT dose (Gy) | LR | OS (%) | Colostomy | Late toxicity ≥ G3 [%] | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Initial | Boost | LRR (%) | LCR (%) | CR % | CFS % | ||||||
Northover et al. (2010) [5] | 2DRT | 290 | 157 | 45 | N/A | 57.1 (5 y) | 33.7 (5 y) | 53 (5 y) | 36.8 (5 y) | N/A | |
Northover et al. (2010) [5] | 2DRT + CT | 295 | 157 | 45 | N/A | 32.3 (5 y) | 46.6 (5 y) | 58.1 (5 y) | 46.9 (5 y) | N/A | |
Ajani et al. (2008) [23] | 2DRT MMC-arm | 324 | 30 | 45 | 10-14 | 25 (5 y) | 84% (5 y) | 10% (5y) | 11% | ||
Kachnic et al. (2013) [24] | IMRT | 43 | 24 | 42* | 50.4* | 95% (2 y) | 94% (2 y) | 90% (2 y) | 7% | ||
50.4** | 54** | ||||||||||